Reply: Antiplatelet Use in Ischemic Stroke.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1386, doi. 10.1177/10600280221096865
- By:
- Publication type:
- Article
Works matching IS 10600280 AND DT 2022 AND VI 56 AND IP 12
Results: 14
1
2
Comment: Antiplatelet Use in Ischemic Stroke.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1384, doi. 10.1177/10600280221096862
- By:
- Publication type:
- Article
3
Criminal Action Against Drug Counterfeiters: Assessment of the FDA Office of Criminal Investigation Database 2016 Through 2021.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1333, doi. 10.1177/10600280221092482
- By:
- Publication type:
- Article
4
Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1376, doi. 10.1177/10600280221090590
- By:
- Publication type:
- Article
5
Rosuvastatin-Induced Dysarthria: An Unusual Drug Reaction.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
6
Balanced Salt Solutions for Critically Ill Patients: Nonplused and Back to Basics.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1365, doi. 10.1177/10600280221084380
- By:
- Publication type:
- Article
7
Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1289, doi. 10.1177/10600280221090211
- By:
- Publication type:
- Article
8
Valproate: Not All Boxed Warnings Are Created Equal.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1349, doi. 10.1177/10600280221085991
- By:
- Publication type:
- Article
9
Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1315, doi. 10.1177/10600280221089008
- By:
- Publication type:
- Article
10
Evaluation of Ceftazidime Use in the Neonatal Intensive Care Unit and Association With Cephalosporin-Resistant Gram-Negative Bacteria.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1325, doi. 10.1177/10600280221088270
- By:
- Publication type:
- Article
11
Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1339, doi. 10.1177/10600280221082326
- By:
- Publication type:
- Article
12
Adalimumab-Adbm: The First Interchangeable Biosimilar for the Treatment of Inflammatory Diseases.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1356, doi. 10.1177/10600280221082196
- By:
- Publication type:
- Article
13
Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1299, doi. 10.1177/10600280221085551
- By:
- Publication type:
- Article
14
Effectiveness and Safety of Lower Dose of Rivaroxaban for Cancer-Related Venous Thromboembolism: A Retrospective Cohort Study.
- Published in:
- Annals of Pharmacotherapy, 2022, v. 56, n. 12, p. 1308, doi. 10.1177/10600280221084418
- By:
- Publication type:
- Article